NCT00409500已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Interleaved, Ascending Dose Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AQW051; to Evaluate the Effect of Food on the Pharmacokinetics of AQW051, in Japanese Healthy Male Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Safety and tolerability of single oral doses of AQW051 in Japanese healthy male subjects at the end of the study
研究概览
简要总结
This study will evaluate safety, tolerability and pharmacokinetics of individual oral doses of AQW051 in Japanese healthy male subjects, and will also evaluate the effect of food on the pharmacokinetics of AQW051.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Japanese healthy male subjects age 20 to 45 years of age, and in good health
- •At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis.
- •Body mass index within the range of 17 to 25 kg/m2 and weigh at least 50 kg
排除标准
- •Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports tobacco use or has a urine cotinine 'high' level in checking by NicCheck® I.
- •Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable.
- •Participation in any clinical investigation within 4 months prior to study start.
- •Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to study start.
- •Subjects considered unsuitable for participation in the study within 2 weeks prior to dosing.
- •A past medical history of clinically significant abnormality detected during electrocardiogram (ECG) examination or an evident family history (grandparents, parents and siblings) of a ECG abnormality (i.e. prolonged QT-interval syndrome).
- •History of fainting, hypotension when standing up, arrhythmia.
- •History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
- •History of clinically significant drug allergy, history or presence of atopic allergy (asthma, urticaria, eczematous dermatitis) unless inactive seasonal allergy, or history of food allergy. A known hypersensitivity to the study drug or drugs similar to the study drug.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
- •History of immunodeficiency diseases, including a positive HIV test result.
- •A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.
- •History of drug or alcohol abuse within the 12 months prior to study participation or evidence of such abuse as indicated by the laboratory assays conducted at screening.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Safety and tolerability of single oral doses of AQW051 in Japanese healthy male subjects at the end of the study
次要结局
- Pharmacokinetics of single oral doses of AQW051 in Japanese healthy male subjects at the end of the study
- Effect of food on the pharmacokinetics of AQW051 after each dose
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.HealthyNCT00418002Novartis72
已完成
1 期
Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersRespiratory Syncytial Virus InfectionsNCT01906164Alios Biopharma Inc.101
终止
2 期
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis Secondary to Systemic SclerosisNCT00581997Novartis Pharmaceuticals8
已完成
1 期
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCentral Nervous System DiseasesAlzheimer's DiseaseNCT00766363FORUM Pharmaceuticals Inc49
已完成
2 期
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseDyskinesiasDrug-inducedNCT01474421Novartis Pharmaceuticals71